Ambrx Biopharma, Inc. (AMAM)

NYSE: AMAM · IEX Real-Time Price · USD
0.520
+0.020 (3.94%)
At close: Dec 5, 2022 3:58 PM
0.550
+0.030 (5.83%)
After-hours: Dec 5, 2022 4:39 PM EST
3.94%
Market Cap 19.31M
Revenue (ttm) 7.46M
Net Income (ttm) -68.08M
Shares Out 270.14M
EPS (ttm) 6.16
PE Ratio 0.08
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 718,918
Open 0.51
Previous Close 0.5
Day's Range 0.49 - 0.56
52-Week Range 0.45 - 10.5
Beta n/a
Analysts Buy
Price Target 3.06 (+488.8%)
Earnings Date n/a

About AMAM

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is a... [Read more]

Industry Biotechnology
IPO Date Jun 18, 2021
Employees 81
Stock Exchange NYSE
Ticker Symbol AMAM
Full Company Profile

Financial Performance

In 2021, AMAM's revenue was $7.46 million, a decrease of -45.47% compared to the previous year's $13.67 million. Losses were -$68.08 million, 311.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for AMAM stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 488.80% from the latest price.

Price Target
$3.06
(488.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Interim Data from Ambrx's Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Can...

Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic breast cancer who have progressed following treatment with T-DM1 Investigators to present efficacy...

6 days ago - GlobeNewsWire

Ambrx Announces NovoCodex's Dosing of First Patient with ARX305, Ambrx's Investigational Antibody Drug Conjugate Targ...

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibo...

3 weeks ago - Business Wire

Ambrx Biopharma Inc. Appoints Daniel O'Connor as Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

1 month ago - Business Wire

Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

- Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 –

1 month ago - GlobeNewsWire

Ambrx Biopharma to Host Corporate Update Conference Call

Conference call to discuss outcome of the strategic review that was initiated in August 2022 Conference call to discuss outcome of the strategic review that was initiated in August 2022

1 month ago - GlobeNewsWire

Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

3 months ago - Business Wire

Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

3 months ago - Business Wire

Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

5 months ago - Business Wire

Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

5 months ago - Business Wire

Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

5 months ago - Business Wire

Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

6 months ago - Business Wire

Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

6 months ago - Business Wire

Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

6 months ago - Business Wire

Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

7 months ago - Business Wire

Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

7 months ago - Business Wire

Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial

Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE: AMAM) have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-S...

7 months ago - Benzinga

Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Pha...

SAN DIEGO--(BUSINESS WIRE)--Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic c...

7 months ago - Business Wire

Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

7 months ago - Business Wire

Ambrx Biopharma Inc. Sponsored ADR (AMAM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Ambrx Biopharma Inc. Sponsored ADR (AMAM), indicating that the stock has found support. This, combined with an upward trend in ...

7 months ago - Zacks Investment Research

Ambrx Biopharma Inc. to Present at Oppenheimer's 32nd Annual Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biol...

8 months ago - Business Wire

Ambrx Biopharma Inc. to Participate in the Cowen 42nd Annual Health Care Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biol...

9 months ago - Business Wire

Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biol...

9 months ago - Business Wire

Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Bio...

9 months ago - Business Wire

Ambrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy?

Ambrx Biopharma (AMAM) has been struggling lately, but the selling pressure may be coming to an end soon.

11 months ago - Zacks Investment Research

Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial

Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-Breast-01 Phase 1 study of ARX788 at the San Antonio...

11 months ago - Benzinga